Krystal Biotech (KRYS) Stock Forecast & Price Target
Krystal Biotech (KRYS) Analyst Ratings
Bulls say
Krystal Biotech Inc. has demonstrated robust financial performance, with $91.1 million in net revenue from Vyjuvek in the latest quarter, reflecting a 9% increase from the prior quarter and aligning with full-year projections of $290.5 million. The successful lung delivery and improved survival results from preclinical studies of their gene therapy platform indicate significant potential for future product development in the oncology space. Furthermore, the company's disciplined operational spending coupled with projected expansions and potential share repurchase programs positions it favorably as a growth-at-a-reasonable-price (GARP) investment opportunity.
Bears say
Krystal Biotech's stock outlook appears negative due to a decline in new reimbursement approvals, with projected decreases from 70 new adds in Q2 2024 to 50 by Q4 2024, highlighting challenges in sustaining revenue growth. Furthermore, despite increased competition thinning in certain gene therapy markets, the company faces potential setbacks linked to the inherent complexities of gene therapy development, including manufacturing difficulties and the unpredictable nature of clinical trial outcomes. Additionally, concerns related to patient recruitment in a competitive and rare disease landscape could further impede the company's ability to realize its financial objectives and advance its development pipeline effectively.
This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.
Krystal Biotech (KRYS) Analyst Forecast & Price Prediction
Start investing in Krystal Biotech (KRYS)
Order type
Buy in
Order amount
Est. shares
0 shares